Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, ##STR00001##
and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,

##STR00001##

and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,

##STR00001##

and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

The invention relates to lipid compounds of formula (I) and their pharmaceutically acceptable salts for the prevention and/or treatment of ophthalmic disorders such as retinal degenerative disorders and ocular inflammatory diseases: (I) (wherein R.sup.1 is either a C.sub.9 to C.sub.22 alkyl group, or a C.sub.9 to C.sub.22 alkenyl group having from 1 to 6 double bonds; R.sup.2 is selected from the group consisting of a halogen atom, a hydroxy group, an alkyl group, an alkoxy group, an alkylthio group, a carboxy group, an acyl group, an amino group, and an alkylamino group; R.sup.3 is a hydrogen atom, or a group R.sup.2; R.sup.4 is a carboxylic acid or a derivative thereof; and X is methylene (CH.sub.2), or an oxygen or sulfur atom).

##STR00001##

The invention relates to lipid compounds of formula (I) and their pharmaceutically acceptable salts for the prevention and/or treatment of ophthalmic disorders such as retinal degenerative disorders and ocular inflammatory diseases: (I) (wherein R.sup.1 is either a C.sub.9 to C.sub.22 alkyl group, or a C.sub.9 to C.sub.22 alkenyl group having from 1 to 6 double bonds; R.sup.2 is selected from the group consisting of a halogen atom, a hydroxy group, an alkyl group, an alkoxy group, an alkylthio group, a carboxy group, an acyl group, an amino group, and an alkylamino group; R.sup.3 is a hydrogen atom, or a group R.sup.2; R.sup.4 is a carboxylic acid or a derivative thereof; and X is methylene (CH.sub.2), or an oxygen or sulfur atom).

##STR00001##

The present invention relates to the technical field of organic chemistry, specifically an asymmetrical hydrogenation of an -ketonic acid compound, the technical proposal being as shown by the following formula: ##STR00001## Wherein R.sup.1 is a phenyl, a substituted phenyl, a naphthyl a substituted naphthyl, a C.sub.1-C.sub.6 alkyl or aralkyl, the substitute is a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkoxy, a halogen, the number of the substituents is 1-3. M is a chiral spiro-pyridyl amido phosphine ligand iridium complex having the following structure, ##STR00002## Wherein, R is hydrogen, 3-methyl, 4-.sup.tBu or 6-methyl

The present invention relates to the technical field of organic chemistry, specifically an asymmetrical hydrogenation of an -ketonic acid compound, the technical proposal being as shown by the following formula: ##STR00001## Wherein R.sup.1 is a phenyl, a substituted phenyl, a naphthyl a substituted naphthyl, a C.sub.1-C.sub.6 alkyl or aralkyl, the substitute is a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkoxy, a halogen, the number of the substituents is 1-3. M is a chiral spiro-pyridyl amido phosphine ligand iridium complex having the following structure, ##STR00002## Wherein, R is hydrogen, 3-methyl, 4-.sup.tBu or 6-methyl

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, ##STR00001##
and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

The invention relates to a compound according to formula I wherein when R.sub.5 is H, and R.sub.1 and R.sub.2 form a ring system, then said compound is selected from the following compounds of formula II or formula IV or when R.sub.2 is H, and R.sub.1 and R.sub.5 form a ring system, then said compound has formula III. ##STR00001##

The invention relates to a compound according to formula I wherein when R.sub.5 is H, and R.sub.1 and R.sub.2 form a ring system, then said compound is selected from the following compounds of formula II or formula IV or when R.sub.2 is H, and R.sub.1 and R.sub.5 form a ring system, then said compound has formula III. ##STR00001##